Aakha Biologics Partners with March Biosciences to Advance Next-Generation Cell Therapies
Frisco-based Aakha Biologics, a North Texas biotechnology company developing multi-specific antibodies for cancer and autoimmune diseases, has entered into a licensing agreement with Houston’s March Biosciences. The deal allows March to integrate Aakha’s proprietary antibody into its expanding cell therapy pipeline targeting treatment-resistant cancers. Under the agreement, Aakha will receive upfront and milestone payments, as well as potential future royalties, further validating its antibody engineering platform.
Aakha Biologics Partners with March Biosciences to Advance Next-Generation Cell Therapies